Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
24. Februar 2021 07:20 ET
|
Kura Oncology, Inc.
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a...
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
24. Februar 2021 07:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Four Upcoming Investor Conferences
18. Februar 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
17. Februar 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
07. Januar 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
06. Januar 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
11. Dezember 2020 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the JMP Securities Hematology Summit
10. Dezember 2020 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
05. Dezember 2020 12:30 ET
|
Kura Oncology, Inc.
– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a...
Kura Oncology to Participate in Three Upcoming Investor Conferences
04. November 2020 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...